Category: oncology retractions

Cancer issues expression of concern about two Henschke I-ELCAP lung cancer screening papers

The journal Cancer has issued an Expression of Concern about two lung cancer screening papers long dogged by doubt.

Last April, The Cancer Letter and The New York Times jointly published an investigation into the International Early Lung Cancer Action Program (I-ELCAP) run by Claudia Henschke and David Yankelevitz. Other researchers had already criticized the design and conclusions of that trial, but as the investigation noted, an October 2008 review of the study found that the researchers couldn’t find 90 percent of the subjects’ consent forms, an ethical no-no that jeopardizes as many as 135 papers.

Two papers published in Cancer, in 2000 and 2001, are among those studies, according to the notice (links added), which credits the Times and The Cancer Letter and notes that the journal has referred the case to Federal investigators: Continue reading Cancer issues expression of concern about two Henschke I-ELCAP lung cancer screening papers

Hopkins scientists retract prostate cancer screening study at center of 2009 lawsuits

The authors of a study in Urology that was at the center of two 2009 lawsuits brought by a company that funded the work have retracted the paper.

The idea behind the research — by Robert Getzenberg and colleagues at Johns Hopkins — was to find an alternative to the prostate specific antigen (PSA) test, which many urologists recommend, but which many groups — including the US Preventive Services Task Force — find wanting. The work gave rise to a company, Onconome, Science reported in a 2009 story about the lawsuits: Continue reading Hopkins scientists retract prostate cancer screening study at center of 2009 lawsuits

Why editors should stop ignoring anonymous whistleblowers: Our latest LabTimes column

A retraction notice appeared a few months ago in the Biophysical Journal:

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).

This article has been retracted at the request of Edward Egelman, Editor-in-Chief.

The editors have noted that there is a substantial overlap of figures and text between this Biophysical Journal article and D. Rutkauskas, V. Novoderezkhin, R.J. Cogdell and R. van Grondelle. Fluorescence spectral fluctuations of single LH2 complexes from Rhodopseudomonas acidophila strain 10050. Biochemistry, 43 (2004) 4431–4438, doi:10.1021/bi0497648. The submission of this paper was inconsistent with the Biophysical Journal policy which states: “Manuscripts submitted to Biophysical Journal (BJ) must be original; papers that have already been published or are concurrently submitted elsewhere for publication are not acceptable for submission. This includes manuscripts previously submitted to BJ, as well as material that has been submitted to other journals while BJ is considering the manuscript. If some part of the work has appeared or will appear elsewhere, the authors must give the specific details of such appearances in the cover letter accompanying the BJ submission. If previously published illustrative material, such as figures or tables, must be included, the authors are responsible for obtaining the appropriate permissions from the publisher(s) before the material may be published in BJ”. We are therefore retracting the publication of the Biophysical Journal article.

Ordinarily, such duplications go to the bottom of our list of retractions to cover, despite how common they are. There’s usually less of a story behind them than there is behind a completely opaque notice, or behind one that sports a whiff of fraud. But they’re still important, as Bruce Chabner, the editor of The Oncologist, pointed out in a recent issue of his journal in which a duplication retraction appeared: Continue reading Why editors should stop ignoring anonymous whistleblowers: Our latest LabTimes column

Cancer journal retracts herbal medicine paper, citing misconduct probe

The journal Cancer Prevention Research has retracted a 2009 article by a group of scientists from the University of Kentucky after the institution determined that one of the figures in the article wasn’t kosher.

The article, “Psoralidin, an Herbal Molecule, Inhibits Phosphatidylinositol 3-Kinase–Mediated Akt Signaling in Androgen-Independent Prostate Cancer Cells,” has been cited 9 times, according to Thomson Scientific’s Web of Knowledge. Earlier iterations of the research were presented at two cancer meetings in 2008.

Continue reading Cancer journal retracts herbal medicine paper, citing misconduct probe

New in PNAS: Potti retraction number seven, and a Potti correction

The Proceedings of the National Academy of Sciences (PNAS) has published the seventh retraction for former Duke researcher Anil Potti, who now faces a lawsuit in the midst of an ongoing investigation into his work:

Retraction for “A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities,” by Katherine S. Garman, Chaitanya R. Acharya, Elena Edelman, Marian Grade, Jochen Gaedcke, Shivani Sud, William Barry, Anna Mae Diehl, Dawn Provenzale, Geoffrey S. Ginsburg, B. Michael Ghadimi, Thomas Ried, Joseph R. Nevins, Sayan Mukherjee, David Hsu, and Anil Potti, which appeared in issue 49, December 9, 2008, of Proc Natl Acad Sci USA (105:19432–19437; first published December 2, 2008; 10.1073/pnas.0806674105).

The authors wish to note the following: “We wish to retract this article because we have been unable to reproduce certain key experiments described in the paper regarding validation and use of the colon cancer prognostic signature. This includes the validation performed with dataset E-MEXP-1224, as reported in Fig. 2A, as well as the generation of prognostic scores for colon cancer cell lines, as reported in Fig. 4. Because these results are fundamental to the conclusions of the paper, the authors formally retract the paper. We deeply regret the impact of this action on the work of other investigators.”

The 2008 paper, which has been cited 27 times, according to Thomson Scientific’s Web of Knowledge, was already the subject of a minor 2009 correction: Continue reading New in PNAS: Potti retraction number seven, and a Potti correction

Lack of ethical approval leads to JCO retraction

The Retraction Watch category for “lack of IRB approval” as a reason for retraction — a subject we covered in our most recent Lab Times column — is growing. First there were the 90-odd retractions by Joachim Boldt, then three by Australian researchers studying Aussie-rules football players. Now, we learn that the Journal of Clinical Oncology has retracted a paper over concerns that the authors failed to obtain ethical approval to conduct their study.

The 2010 publication, by researchers at Saitama Medical University in Japan, reported on an analysis of 314 lymphoma patients being treated with chemotherapy — some, and perhaps none, of whom knew they were being studied.

Here’s the notice, which appeared this month: Continue reading Lack of ethical approval leads to JCO retraction

Duke sued over Potti case

Anil Potti, courtesy Duke

From the “not terribly surprising” department: Eight patients — or their estates — who enrolled in clinical trials at Duke overseen by Anil Potti and colleagues have sued the university.

The 90-page lawsuit, which names Duke, Potti, Potti’s boss Joseph Nevins, CancerGuide Diagnostics (in which Potti and Nevins had an interest), among others, does a thorough job of documenting the case. In particular, it reviews the history of the trials, which were stopped in 2009, restarted, and then stopped for good as more and more issues came to light. It emphasizes, as you would expect, that Duke and the Potti team were warned repeatedly about problems in their work, notably by Keith Baggerly and a colleague.

Potti and colleagues have, as Retraction Watch readers will remember, now retracted five papers.

The plaintiff’s attorney, Thomas Henson, told Raleigh-Durham’s ABC11: Continue reading Duke sued over Potti case

Two papers to be retracted after ORI finds misconduct by Boston University cancer researcher

courtesy Nature Publishing Group

The U.S. Department of Health and Human Services’ Office of Research Integrity (ORI) has found that a Boston University cancer researcher made up experiments reported in two papers funded by National Cancer Institute and National Institutes of Health grants. According to the ORI notice:

Sheng Wang, PhD, Boston University School of Medicine Cancer Research Center: Based on the Respondent’s acceptance of ORI’s research misconduct findings, ORI found that Dr. Sheng Wang, who has been an Assistant Professor, Department of Medicine, Boston University School of Medicine Cancer Research Center (BUSM), engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grants R01 CA102940 and R01 CA101992.

The two papers were: Continue reading Two papers to be retracted after ORI finds misconduct by Boston University cancer researcher

Should we change our name to Mori Watch? Yet another retraction from cancer researcher

Earlier this week we reported on the latest retraction of an article by Naoki Mori, number 21 in a series. We could have waited a few days and saved ourselves some trouble.

The journal Leukemia Research has retracted a 2006 paper by Mori, titled “Curcumin suppresses constitutive activation of AP-1 by downregulation of JunD protein in HTLV-1-infected T-cell lines.” From the notice, which is behind a paywall: Continue reading Should we change our name to Mori Watch? Yet another retraction from cancer researcher

Anil Potti resurfaces at South Carolina cancer center

courtesy Duke

Anil Potti, the oncologist who has been forced to retract four papers because of results that could not be reproduced, and resigned last fall from Duke, has a new job. He’s joined the Coastal Cancer Center, an oncology practice with four offices in South Carolina and one in North Carolina.

The Duke Fact Checker was apparently the first to report the news. The Cancer Letter, which has been out front on the Potti story for a year, first reported the news.*

It’s not surprising that Potti’s Coastal Center bio leaves out any mention of his troubled research and the fact that he faked a Rhodes scholarship on a grant application. Investigations into what happened at Duke are ongoing. Continue reading Anil Potti resurfaces at South Carolina cancer center